Floatz logo

Tak-228

Recurrent Lung Non-Small Cell Carcinoma

Faeth TherapeuticsPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Rucaparib
SWOG Cancer Research Network
Phase 2B
Nelfinavir
University of Washington
Phase 2CCC
Onalespib
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →
uterine corpus cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →